# Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Subjects with a History of Life Threatening/Seriously Debilitating Asthma Who Participated in the MEA115661 Trial

Published: 27-03-2014 Last updated: 20-04-2024

Primary: To provide extended treatment with mepolizumab to subjects with severe asthma and a history of improved disease control while receiving mepolizumab as defined by this protocol. Secondary: To collect data on long term clinical data.

Ethical review Approved WMO

**Status** Recruitment stopped

**Health condition type** Bronchial disorders (excl neoplasms)

**Study type** Interventional

### **Summary**

#### ID

NL-OMON44315

Source

**ToetsingOnline** 

**Brief title** 

MEA201312

#### Condition

• Bronchial disorders (excl neoplasms)

#### **Synonym**

bronchial asthma; asthma

#### Research involving

### **Sponsors and support**

Primary sponsor: GlaxoSmithKline

Source(s) of monetary or material Support: GlaxoSmithKline BV

#### Intervention

**Keyword:** asthma, follow-up, mepolizumab

#### **Outcome measures**

#### **Primary outcome**

NA.

#### **Secondary outcome**

Adverse events, antibodies, exacerbations, asthma control questionnaire, FEV1.

# **Study description**

#### **Background summary**

Mepolizumab is currently under clinical development for severe asthma. Mepolizumab is a humanized antiinterleukin 5 (anti-IL5) antibody (IgG Kappa) that binds to and inactivates IL-5. IL-5 is the principle eosinophilic regulatory cytokine. It is critical for the development and release of eosinophils from the bone marrow, enhances adhesion to endothelial cells, and promotes the persistence and activation of eosinophils. Eosinophils are thought to play a major role in maintaining airway inflammation. Mepolizumab binds with high affinity to human interleukin-5 and blocks its binding to and the activation of the IL-5 receptor (CD125). It is hypothesized that blocking IL-5 with mepolizumab will have a positive effect in reducing eosinophilic inflammation in patients with severe refractory asthma who are dependent on maintenance steroid to treat their asthma. This concept has been previously investigated in a small study (N=20) of asthmatics with persistent sputum eosinophils. The results of this study demonstrated that mepolizumab was well tolerated and effective in reducing the dose of prednisone while preventing exacerbations, decreasing blood and sputum eosinophil numbers, and improving lung function and quality of life.

Recently a study of IV mepolizumab of over 600 subjects with severe refractory uncontrolled asthma has been completed. All 3 doses investigated (75mg, 250 mg

and 750mg) resulted in a clinically significant reduction in the frequency of severe exacerbations when compared to placebo and produced a marked and sustained suppression of blood eosinophils. The safety profile was similar across all treatment arms and was similar to placebo.

A PK/PD model has been developed for mepolizumab with data obtained from prior studies. Two of these 5 studies administered mepolizumab via the subcutaneous (SC) route. The model well describes the relationship between plasma mepolizumab concentration and eosinophil counts (irrespective of the route of administration. Based on prior PK studies, the bioavailability of mepolizumab administered SC is approximately 75% and therefore a dose of 100mg SC is anticipated to provide similar exposure to the 75mg IV effective dose. A SC route of administration has been chosen for the current study as it is generally preferred by patients and is easy to administer.

The current study is an extension of the study MEA115661 (that was itself an extension study of MEA115575). Patients who have completed this previous study may use mepolizumab in this extension study. The purpose is primarily to guarantee further availability of mepolizumab to the trial subjects until the drug is available on prescription in our country.

#### Study objective

Primary: To provide extended treatment with mepolizumab to subjects with severe asthma and a history of improved disease control while receiving mepolizumab as defined by this protocol.

Secondary: To collect data on long term clinical data.

#### Study design

Open-label non-comparative phase III study. Treatment with Mepolizumab 100 mg s.c. every 4 weeks

Continuation of standard treatment for asthma.

Salbutamol rescue medication.

Study duration max. 3 year and 4 months.

Follow-up phase 4 weeks.

Approx. 375 patients.

#### Intervention

Treatment with mepolizumab.

#### Study burden and risks

Risk: adverse events of study treatment.

Burden: approx. 45 visits in max. 3 year and 4 months. Duration 1-2h.

S.c. injections (1 ml) with mepolizumab every 4 weeks during max. 3 year and 4 months.

Blood draws every 6 months (approx. 10 ml/occasion).

Pregnancy test every visit.

Physical examination 2x.

Pulmonary function test every 6 months.

ECG every 6 months during the first 2 years.

Asthma Control Questionnaire every 3 months.

### **Contacts**

#### **Public**

GlaxoSmithKline

Huis ter Heideweg 62 Zeist 3705 LZ NL

#### **Scientific**

GlaxoSmithKline

Huis ter Heideweg 62 Zeist 3705 LZ NL

### **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

- \* Visit 14 of MEA115661 completed.
- \* Asthma has been treated with an ICS for the last 8 months with fluticasone propionate \*500 mcg/day (or equivalent).
- \* Life-threatening /serious debilitating asthma (see protocol page 23 for details).
  - 4 Study 201312: A Multi-Centre, Open-Label, Study of Mepolizumab in a Subset of Su ... 27-06-2025

- \* Documented clinical benefit (see protocol page 24 for details).
- \* Adequate contraception during the study and the following 4 months for females of childbearing potential.
- \* If either criteria on disease severity or clinical benifit are not met: subjects who are considered to be at risk of experiencing a life-threatening event, or whose functional health status will become significantly worse if returned to standard of care, as judged by the investigator and agreed by GSK.

#### **Exclusion criteria**

- \* Received placebo in MEA115575 and able to discontinue oral corticosteroid therapy by the end of the study.
- \* Pregnancy or breastfeeding
- \* Current smokers.
- \* Baseline ECG which has a clinically significant abnormality.

# Study design

### **Design**

Study phase: 3

Study type: Interventional

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Treatment

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 14-07-2014

Enrollment: 11

Type: Actual

### Medical products/devices used

Product type: Medicine

Brand name: mepolizumab

Generic name: mepolizumab

# **Ethics review**

Approved WMO

Date: 27-03-2014

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 26-06-2014

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 08-08-2014

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 12-08-2014

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 31-12-2014

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 20-01-2015

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 12-11-2015

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 18-11-2015

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 29-01-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 18-02-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 06-06-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 06-07-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 16-09-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 22-09-2016

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

# **Study registrations**

### Followed up by the following (possibly more current) registration

No registrations found.

# Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

Other clinicaltrials.gov; registratienummer n.n.b.

EudraCT EUCTR2014-000314-54-NL

CCMO NL48592.060.14